Comparative guide · 6 min read

Ginkgo vs Bacopa for memory — which actually has trial evidence in adults

Updated 2026-05-17 · Reviewed by SupplementScore editors · No sponsorships

Ginkgo biloba and Bacopa monnieri are the two most consistently marketed "memory herbs." They occupy quite different evidence profiles. Ginkgo (standardised EGb 761 extract) has been studied in older adults with mild cognitive complaints with mixed but mostly modest results; large prevention trials like GEM and GuidAge were negative for dementia incidence. Bacopa has small but cleaner trials in healthy adults showing modest improvement in verbal memory after 8–12 weeks. Neither is a substitute for sleep, exercise, or treating an underlying cause.

Quick verdict

GoalBetter choiceWhy
Verbal memory in healthy adults, chronic useBacopaSeveral 8–12-week RCTs at 300 mg/day standardised extract show modest improvement on word-pair recall and delayed recall.
Cognitive complaints with cerebrovascular concern in older adultsGinkgo (EGb 761)Some signal in vascular cognitive impairment; trial heterogeneity is high.
Dementia preventionNeitherGEM (2008) and GuidAge (2012) — large RCTs of EGb 761 — did not reduce dementia incidence.
Acute, same-day cognitive boostNeitherBoth work (if at all) over weeks. Caffeine + L-theanine is the better acute pairing.
TolerabilityGinkgoBacopa frequently causes GI upset, especially without food; ginkgo is generally well tolerated.
Drug-interaction footprintBacopaGinkgo has additive bleeding risk with anticoagulants and antiplatelets; bacopa's interaction list is smaller.

How they actually work

Ginkgo biloba (EGb 761) — vasodilation and antioxidant claims

Ginkgo's standardised EGb 761 extract contains roughly 24% flavone glycosides and 6% terpene lactones (ginkgolides, bilobalide). Proposed mechanisms include modest vasodilation, antioxidant activity, and platelet-activating-factor inhibition. The most-cited trials are in older adults with mild cognitive impairment or in age-associated memory complaints, with response heterogeneous across patient selection and outcome measure.

Bacopa monnieri — cholinergic and dendritic effects

Bacopa contains bacosides (the active marker compounds, standardised to 20–55% in commercial extracts). Animal work suggests upregulation of dendritic arborisation and cholinergic activity. In humans, the consistent — but modest — signal is on delayed recall and word-pair learning after 8–12+ weeks at 300 mg/day standardised extract. Acute studies are negative; this is a chronic-use intervention.

Memory in healthy adults

Bacopa's strongest signal is here: meta-analyses of RCTs in healthy adults show small but statistically reliable improvements in delayed verbal recall and speed of information processing after 12 weeks of 300 mg/day. Effect sizes are modest (Cohen's d around 0.2–0.3) — meaningful at a population level but unlikely to be subjectively transformative. Ginkgo in the same population has not shown a comparable signal.

Older adults with cognitive complaints

Ginkgo's case is here, not in healthy young adults. EGb 761 240 mg/day for 22+ weeks has shown modest improvement on cognitive function scales in patients with mild cognitive impairment and in dementia (as adjunct). The 2009 Cochrane review concluded the evidence for clinically significant benefit is "inconsistent and unconvincing." Both GEM (2008, 3000+ adults, 6 years) and GuidAge (2012, 2800+ adults, 5 years) — large primary-prevention trials of EGb 761 — did not reduce dementia incidence.

Mood and anxiety

Bacopa has a small signal on anxiety scales in some trials; ginkgo less so. Neither is a primary anxiolytic choice — saffron, ashwagandha, and L-theanine all have stronger trial signals.

Practical rule. If you're a healthy adult wanting a low-risk chronic memory intervention, Bacopa (300 mg/day standardised, with food, for at least 12 weeks) has the cleaner case. If you're an older adult with vascular risk factors and mild cognitive complaints, EGb 761 240 mg/day is a reasonable trial — but expect modest effect at best, and not a dementia-prevention intervention.

Dose, form, and timing

Ginkgo: 120–240 mg/day of EGb 761 standardised extract (24% flavone glycosides / 6% terpene lactones), divided BID. Generic ginkgo preparations vary widely — the trial evidence is specific to EGb 761. Trial duration is typically 22+ weeks.

Bacopa: 300 mg/day of extract standardised to 50–55% bacosides (e.g., BacoMind, KeenMind/CDRI 08). Take with food to limit GI upset. 8–12+ weeks before assessing effect. Tablets are convenient; powder has a bitter taste.

Safety

Ginkgo: well-tolerated; rare allergic reactions. Key issue is additive bleeding risk with anticoagulants (warfarin, DOACs), antiplatelets (aspirin, clopidogrel), and NSAIDs. Discontinue 1–2 weeks before surgery. Pregnant patients should avoid.

Bacopa: GI upset (nausea, increased stool frequency, cramping) is the most common complaint — usually mitigated by taking with food. Sedation in some users. Theoretical caution in patients on thyroid medication (TSH effects in small studies). Generally compatible with most medications.

Cost

Ginkgo (standardised EGb 761): $0.15–0.40 per daily dose. Bacopa: $0.20–0.50 per daily dose. Both are inexpensive on a monthly basis.

Who should pick each

Pick Bacopa if: you're a healthy adult, want a low-risk chronic memory intervention, can commit to 8–12+ weeks of consistent use, tolerate herbal supplements with food.

Pick Ginkgo (EGb 761) if: you're an older adult with mild cognitive complaints and concurrent vascular concerns, not on anticoagulants/antiplatelets, willing to trial for 6+ months. Use a standardised EGb 761 preparation, not generic ginkgo.

Pick neither if: you want a same-day boost (try caffeine + L-theanine, or look at sleep first), you want a dementia-prevention intervention (the trial evidence does not support it for either), or you're on anticoagulants without supervised care.

What we'd actually buy

For a healthy 30–50-year-old with subjective memory complaints: address sleep first; check B12, ferritin, thyroid, vitamin D; then trial Bacopa 300 mg/day standardised for 12 weeks. For a 70-year-old with vascular risk and mild cognitive complaints, not on anticoagulants: EGb 761 240 mg/day for 6 months alongside aerobic exercise and cognitive activity.

Sources

Read more: